This week, I had an insightful conversation with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. We discussed the intricacies of different Public Offering strategies, including micro IPOs, which offer a unique avenue for biotech companies. David provides a deep perspective on the strategic implications of IPOs for biotech funding. He emphasized the importance of investor support and strategic banking partnerships, especially for micro IPOs. We also discussed the potential of AI in reshaping financial services and the future of outcome-based pricing models in investment. David's personal insights reveal the demanding yet rewarding nature of investment banking and highlight crucial aspects to consider for those pursuing a career in this field.

Connect with us!

Subscribe here:

Learn more about Recruitomics Consulting

Check out our reading list

Download our free startup resources guide to grow your biotech efficiently

If you're on the job market, visit the Collaboratory Career Hub

00:00 Introduction to Biotech and Investment Banking

00:48 David Sands' Background and Career Journey

02:12 Transition from Biotech to Finance

04:53 Understanding Micro IPOs

06:37 Challenges and Strategies in Biotech IPOs

16:38 The Role of the FDA in Biotech IPOs

18:30 Understanding IPO Disparities

18:42 Key Factors for a Successful IPO

19:29 Aftermarket Support and Investor Relations

20:59 The Role of Long-Term Investors

21:34 Personal Investment Strategies

22:29 Innovations in Financial Services

24:40 Challenges for Biotech CEOs

26:32 Career Path in Investment Banking

28:50 Future of Financial Services and AI

33:37 Book Recommendations and Closing Thoughts

Small Offerings, Big Impact: Demystifying Micro-IPOs in Biotech with David Sans, Head of Healthcare Investment Banking at EF Hutton